Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A …
A Ighani, JR Georgakopoulos, NH Shear… - Journal of the American …, 2018 - jaad.org
P values were computed using the Pearson chi-square test, comparing the proportions
reported in the pooled RCTs with those in our cohort (boldface indicates statistically …
reported in the pooled RCTs with those in our cohort (boldface indicates statistically …
Efficacy and safety of apremilast monotherapy for moderate to severe psoriasis: retrospective study
A Ighani, JR Georgakopoulos, LL Zhou… - Journal of …, 2018 - journals.sagepub.com
Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …
[HTML][HTML] Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for≥ 156 weeks from 2 phase 3, randomized, controlled trials …
Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …
Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
A Armstrong, E Levi - Journal of Drugs in Dermatology: JDD, 2017 - europepmc.org
OBJECTIVE: To examine real-world use and patient outcomes with apremilast, an oral
PDE4 inhibitor, in the dermatology practice set-ting for treatment of patients with moderate to …
PDE4 inhibitor, in the dermatology practice set-ting for treatment of patients with moderate to …
Apremilast use in severe psoriasis: real-world data from Central and Eastern Europe
P Cetkovská, I Dediol, M Šola, M Kojanová, K Trčko… - Advances in …, 2023 - Springer
Introduction The broad and sustained efficacy of apremilast for psoriasis has been
demonstrated in randomized and real-world observational studies. Data from Central and …
demonstrated in randomized and real-world observational studies. Data from Central and …
Efficacy and Safety of Apremilast in Systemic-and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
J Bagel, M Lebwohl, JM Jackson, R Chen… - Journal of drugs in …, 2018 - europepmc.org
BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …
Real-world experience of patient-relevant benefits and treatment satisfaction with apremilast in patients with psoriasis: an analysis of the APPRECIATE study
Introduction In the real-world APPRECIATE study (NCT02740218), most patients with
psoriasis demonstrated notable improvements on disease severity measures and reported …
psoriasis demonstrated notable improvements on disease severity measures and reported …
Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study
B Strober, J Bagel, M Lebwohl… - Journal of drugs in …, 2017 - pubmed.ncbi.nlm.nih.gov
INTRODUCTION: Many options are available for patients with moderate to severe plaque
psoriasis. Patients with moderate disease, however, are often undertreated and do not …
psoriasis. Patients with moderate disease, however, are often undertreated and do not …
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled …
Background Patients with mild-to-moderate psoriasis may have substantial quality-of-life
impairment. Objective To evaluate apremilast 30 mg twice daily for mild-to-moderate …
impairment. Objective To evaluate apremilast 30 mg twice daily for mild-to-moderate …
Real-life effectiveness of apremilast for the treatment of psoriasis in Belgium: results from the observational OTELO study
PD Ghislain, J Lambert, XLL Hoai, T Hillary… - Advances in …, 2022 - Springer
Introduction Apremilast is approved for the treatment of psoriasis and psoriatic arthritis.
However, data on the efficacy and safety of apremilast in clinical practice are limited. We …
However, data on the efficacy and safety of apremilast in clinical practice are limited. We …